The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Passenger deletions generate therapeutic vulnerabilities in cancer
Open accessAbstract
Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally deleted gene is a member of a functionally redundant family of genes carrying out an essential function. The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in glioblastoma (GBM), which is tolerated by the expression of ENO2. Here we show that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1-deleted GBM cells relative to ENO1-intact GBM cells or normal astrocytes. The principle of collateral vulnerability should be applicable to other passenger-deleted genes encoding functionally redundant essential activities and provide an effective treatment strategy for cancers containing such genomic events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the gene encoding enolase 1 (ENO1) is on the tumor-suppressor locus 1p36, and undergoes homozygous deletion in 1–5% of GBM cancers. Knockdown of enolase 2 (ENO2) in ENO1-null GBM cells resulted in significant inhibition of proliferation and intracranial tumorigenesis, whereas ENO1 expressing cancer cells were insensitive to ENO2 ablation.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Muller et al., 2012
In the citing paper
“Furthermore, ENO1 loss results in extreme sensitivity to the pan-enolase inhibitor phosphonoacetohydroxamate (PHAH) and SF2312 (Leonard et al., 2016; Muller et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Muller et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective killing of cancer cells by a small molecule targeting the stress response to ROS
Raj, L., Ide, T., Gurkar, A. U., Foley, M. A., Schenone, M., Li, X., Tolliday, N. J., Golub, T. R., Carr, S. A., Shamji, A. F., et al. (2011) · Nature · doi:10.1038/nature10167 · Cited by 1,040
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Self-citationFull-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans
Sönnichsen, B., Koski, L. B., Walsh, A., Marschall, P., Neumann, B., Brehm, M., Alleaume, A.-M., Artelt, J., Bettencourt, P. J. G., Cassin, E., et al. (2005) · Nature · doi:10.1038/nature03353 · Cited by 913
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767
Self-citationSignatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 674
Innate versus learned odour processing in the mouse olfactory bulb
Kobayakawa, K., Kobayakawa, R., Matsumoto, H., Oka, Y., Imai, T., Ikawa, M., Okabe, M., Ikeda, T., Itohara, S., Kikusui, T., et al. (2007) · Nature · doi:10.1038/nature06281 · Cited by 659
The Carnegie Protein Trap Library: A Versatile Tool for Drosophila Developmental Studies
Buszczak, M., Paterno, S., Lighthouse, D. V., Bachman, J. L., Planck, J. L., Owen, S., Skora, A. D., Nystul, T. G., Ohlstein, B., Allen, A. K., et al. (2006) · Genetics · doi:10.1534/genetics.106.065961 · Cited by 578
High-resolution genomic profiles of human lung cancer
Tonon, G., Wong, K., Maulik, G., Brennan, C. W., Feng, B., Zhang, Y., Khatry, D., Protopopov, A. I., You, M. J., Aguirre, A. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504126102 · Cited by 398
Self-citationMultiple knockout analysis of genetic robustness in the yeast metabolic network
Deutscher, D., Meilijson, I., Kupiec, M., & Ruppin, E. (2006) · Nature Genetics · doi:10.1038/ng1856 · Cited by 201
The Quest for the 1p36 Tumor Suppressor
Bagchi, A., & Mills, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2095 · Cited by 196
Exposing the fitness contribution of duplicated genes
DeLuna, A., Vetsigian, K., Shoresh, N., Hegreness, M., Colón‐González, M., Chao, S., & Kishony, R. (2008) · Nature Genetics · doi:10.1038/ng.123 · Cited by 177
β‐enolase deficiency, a new metabolic myopathy of distal glycolysis
Comi, G. P., Fortunato, F., Lucchiari, S., Bordoni, A., Prelle, A. C., Jann, S., Keller, A., Ciscato, P., Galbiati, S., Chiveri, L. R., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1095 · Cited by 131
Kotliarov, Y., Steed, M. E., Christopher, N., Walling, J., Su, Q., Heiss, J. D., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1691 · Cited by 127
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma
Mueller, W. C., Nutt, C. L., Ehrich, M., Riemenschneider, M. J., von Deimling, A., van den Boom, D., & Louis, D. N. (2006) · Oncogene · doi:10.1038/sj.onc.1209805 · Cited by 119
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
Duncan, C. G., Killela, P. J., Payne, C. A., Lampson, B. L., Chen, W., Liu, J., Solomon, D. A., Waldman, T. A., Towers, A. J., Gregory, S. G., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.137 · Cited by 114
PARP inhibitors stumble in breast cancer
Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 110
Widespread conservation of genetic redundancy during a billion years of eukaryotic evolution
Vavouri, T., Semple, J. I., & Lehner, B. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.005 · Cited by 109
Yin, D., Ogawa, S., Kawamata, N., Tunici, P., Finocchiaro, G., Eoli, M., Rückert, C., Huynh, T. P., Liu, G., Kato, M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0270 · Cited by 106
A survey of homozygous deletions in human cancer genomes
Cox, C., Bignell, G. R., Greenman, C., Stabenau, A., Warren, W., Stephens, P., Davies, H. R., Watt, S., Teague, J. W., Edkins, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408593102 · Cited by 100
Henrich, K., Bauer, T., Schulte, J. H., Ehemann, V., Deubzer, H. E., Gogolin, S., Muth, D., Fischer, M., Benner, A., König, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3014 · Cited by 100
Reaction intermediate analogs for enolase
Anderson, V. E., Weiss, P. M., & Cleland, W. W. (1984) · Biochemistry · doi:10.1021/bi00307a038 · Cited by 84
Soto, J. A. D., & Deng, C. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.117 · Cited by 71
Inhibition of purified enolases from oral bacteria by fluoride
Guha‐Chowdhury, N., Clark, A. G., & Sissons, C. H. (1997) · Oral Microbiology and Immunology · doi:10.1111/j.1399-302x.1997.tb00623.x · Cited by 69
Peng, W., Shibata, T., Katoh, H., Kokubu, A., Matsuno, Y., Asamura, H., Tsuchiya, R., Kanai, Y., Hosoda, F., Sakiyama, T., et al. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00092.x · Cited by 55
Brookfield, J. F. Y. (1997) · Advances in genetics · doi:10.1016/s0065-2660(08)60308-9 · Cited by 47
Navarro, M. V. A. S., Dias, S. M. G., Mello, L. V., Giotto, M. T. S., Gavalda, S., Blonski, C., Garratt, R. C., & Rigden, D. J. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06027.x · Cited by 46
Poyner, R. R., & Reed, G. H. (1992) · Biochemistry · doi:10.1021/bi00146a020 · Cited by 42
Synthetic lethality-based targets for discovery of new cancer therapeutics.
Weidle, U. H., Maisel, D., & Eick, D. (2011) · PubMed · Cited by 40
Jing, M. X., & Ismail‐Beigi, F. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00321.2005 · Cited by 40
Enolase Activity and Isoenzyme Distribution in Human Brain Regions and Tumors
Joseph, J., Cruz-Sánchez, F., & Carreras, J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062484.x · Cited by 34
Stefanini, M. (1972) · American Journal of Clinical Pathology · doi:10.1093/ajcp/58.5.408 · Cited by 31
Jing, M. X., & Ismail‐Beigi, F. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00196.2006 · Cited by 23
Flagged first, then by citations
Cited by
Sorted by citations
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Understanding the Intersections between Metabolism and Cancer Biology
Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,369
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928
Self-citation
Metadata
- Authors
- Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., Lee, M. A., Hu, B., Hu, J., Sahin, E., Ong, D., Fletcher-Sananikone, E., Ho, D., Kwong, L., Brennan, C., Wang, Y. A., Chin, L., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- DePinho, Ronald A.
- ORCID
- Venue
- Nature
- Published
- 2012-08-15
- Volume
- 488
- Issue
- 7411
- Pages
- 337-342
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3712624
- OpenAlex
- W1982318323
- Cited by
- 339
- References
- 38
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 20 · 2023: 20 · 2022: 32 · 2021: 34 · 2020: 32 · 2019: 32 · 2018: 20 · 2017: 27 · 2016: 18 · 2015: 19 · 2014: 33 · 2013: 14 · 2012: 6
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-07-08)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute (57006984)
- National Eye Institute (R01EY020641)
- National Cancer Institute (P01 CA 95616, T32CA009361, P01CA095616)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- alpha-enolase, neuron-specific enolase, enolase, 1p36 deletion, glioblastoma, housekeeping genes, glycolysis, RNA interference, tumor suppressor, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Brain Neoplasms, Chromosomes, Human, Pair 1, DNA-Binding Proteins, Enzyme Inhibitors, Glioblastoma, Homozygote, Humans, Hydroxamic Acids, Neoplasm Transplantation, Phosphonoacetic Acid, Phosphopyruvate Hydratase, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Sequence Deletion, Genes, Essential, Tumor Suppressor Proteins, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Mice, Gene Knockdown Techniques, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
